Pembrolizumab + MRGOO3 as Neoadjuvant in NPC

The goal of this clinical trial is to evaluate efficacy and safety of neoadjuvant of the anti PD1 agent Pembrolizumab combined with MRG003 and adjuvant treatment of Pembrolizumab in patients with Epstein-Barr virus (EBV) - associated locoregionally advanced nasopharyngeal carcinoma. The expected sample size is 35 patients. Participants will receive 3 cycles of neoadjuvant pembrolizumab 200mg Q3W plus MRG003 2.3mg/kg Q3W followed by the standard concurrent chemoradiotherapy. Then participants will receive 14 cycles of adjuvant Pembrolizumab 200 mg Q3W after the standard concurrent chemoradiotherapy. The estimated average length of treatment per patients is 1 year.

NCT Number	NCT07267338
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Collaborators: Merck Sharp & Dohme LLC, Lepu Medical Technology (Beijing) Co., Ltd.
Conditions	NPC, Locoregionally Advanced Nasopharyngeal Carcinoma
Enrollment	35 participants
Start Date	2026-06
Primary Completion	2027-12 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2025-12-05